UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): January 27, 2017
OWC PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
Commission File No.: 0-54856
| Delaware | 98-0573566 |
| (State of Incorporation) | (I.R.S. Employer Identification No.) |
| | |
| 30 Shacham Street, P.O.B. 8324, Petach Tikva, Israel | 4918103 |
| (Address of Principal Executive Offices) | (ZIP Code) |
Registrant's Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On January 27, 2017, OWC Pharmaceutical Research Corp. issued a press release announcing that Ms. Miri Sani has accepted her nomination to the Company's Advisory Board. The press release is attached to this Form 8-K as Exhibit 99.1.
Exhibit No. | Description |
| 99.1 | Press Release issued by OWC Pharmaceutical Research Corp. dated January 27, 2017. |
| | |
| OWC Pharmaceutical Research Corp. | |
| | | |
| By: | /s/ Mordechai Bignitz |
| Name: | Mordechai Bignitz |
| Title: | Chief Executive Officer |
Date: January 27, 2017
